Future Perspectives and Unmet Needs in Multiple Myeloma
The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Bispecific Antibody Selection in Multiple Myeloma
Clinical insights on selecting the right bispecific antibody for the right patient and an overview of barriers seen in community practice.
Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.
Emerging Research in CAR T-Cell Therapy in R/R Multiple Myeloma
A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.
Later-Line Therapy in Multiple Myeloma
The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.
Treatment Decision-Making and Assessing Frailty in Multiple Myeloma
Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.
Multiple Myeloma: Treatment Considerations and Role of MRD
The panel discusses the effect minimal residual disease (MRD) has on treatment selection and provides insights on the treatment of younger patients with standard risk.
Consolidation and Maintenance Therapy Considerations in Multiple Myeloma
Expert perspectives on the practical applications of consolidation and maintenance therapies for patients with multiple myeloma.
Quad Therapy and Risk Stratification in Multiple Myeloma
Comprehensive insights on quadruplet therapy regimens and the risk stratification process for patients with multiple myeloma.
Determining Candidates for Transplant in Newly Diagnosed Multiple Myeloma
A panel of experts on multiple myeloma discuss newly diagnosed patients and factors that determine transplant eligibility.
